propafenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiarrhythmics, propafenone derivatives	2291	54063-53-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: propafenone propafenone hydrochloride polfenon (RS)-Propafenone propafenone HCl	An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Molecular weight: 341.45 Formula: C21H27NO3 CLOGP: 3.64 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 58.56 ALOGS: -4.65 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

propafenone
propafenone hydrochloride
polfenon
(RS)-Propafenone
propafenone HCl

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.

Molecular weight: 341.45
Formula: C21H27NO3
CLOGP: 3.64
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 58.56
ALOGS: -4.65
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.30	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.09 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	12 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 27, 1989	FDA	GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Atrial fibrillation	215.03	17.39	153	8218	116483	63364168
Electrocardiogram QRS complex prolonged	179.82	17.39	55	8316	5883	63474768
Drug interaction	162.11	17.39	174	8197	228957	63251694
Bradycardia	141.57	17.39	99	8272	73128	63407523
Sinus bradycardia	111.82	17.39	49	8322	14502	63466149
Arrhythmia	84.16	17.39	56	8315	38084	63442567
Completed suicide	68.52	17.39	90	8281	145583	63335068
Cardiac arrest	64.69	17.39	70	8301	92475	63388176
Toxicity to various agents	60.46	17.39	113	8258	247137	63233514
Enzyme induction	54.05	17.39	9	8362	53	63480598
Syncope	52.82	17.39	71	8300	117314	63363337
Intentional overdose	48.18	17.39	54	8317	74098	63406553
Atrioventricular block complete	45.26	17.39	22	8349	8229	63472422
Hypotension	44.88	17.39	106	8265	272498	63208153
Atrial flutter	44.60	17.39	23	8348	9749	63470902
Palpitations	44.43	17.39	64	8307	112706	63367945
Asthenia	43.68	17.39	130	8241	383474	63097177
Cardiogenic shock	43.61	17.39	28	8343	17904	63462747
Bradyarrhythmia	41.12	17.39	14	8357	2101	63478550
International normalised ratio increased	39.41	17.39	39	8332	46386	63434265
Loss of consciousness	37.98	17.39	61	8310	118060	63362591
Systolic dysfunction	36.72	17.39	12	8359	1587	63479064
Nodal arrhythmia	36.16	17.39	11	8360	1152	63479499
Generalised tonic-clonic seizure	35.65	17.39	30	8341	28986	63451665
Dizziness	34.08	17.39	129	8242	429796	63050855
Ventricular tachycardia	31.69	17.39	24	8347	19955	63460696
Electrocardiogram abnormal	29.15	17.39	17	8354	9162	63471489
Tension	28.70	17.39	12	8359	3163	63477488
Granulocytopenia	27.77	17.39	14	8357	5658	63474993
Bundle branch block left	27.64	17.39	15	8356	7044	63473607
Cardiac assistance device user	27.60	17.39	5	8366	51	63480600
Atrioventricular block first degree	27.22	17.39	15	8356	7258	63473393
Pain	26.98	17.39	35	8336	740593	62740058
Coagulation test abnormal	26.76	17.39	8	8363	790	63479861
Haemodynamic instability	26.51	17.39	16	8355	9174	63471477
Bradykinesia	25.97	17.39	13	8358	5175	63475476
Flat affect	25.86	17.39	9	8362	1441	63479210
Conduction disorder	25.76	17.39	9	8362	1458	63479193
Labelled drug-drug interaction medication error	25.57	17.39	18	8353	13381	63467270
Duplicate therapy error	24.81	17.39	5	8366	93	63480558
Suicide attempt	24.59	17.39	35	8336	60883	63419768
Product measured potency issue	24.01	17.39	5	8366	110	63480541
Atrioventricular block	23.85	17.39	14	8357	7633	63473018
Rhabdomyolysis	23.53	17.39	29	8342	43922	63436729
Psychomotor retardation	23.30	17.39	11	8360	3859	63476792
Heart rate irregular	23.15	17.39	21	8350	22400	63458251
Brugada syndrome	22.64	17.39	6	8365	382	63480269
Defect conduction intraventricular	22.62	17.39	5	8366	147	63480504
Ischaemic hepatitis	22.55	17.39	9	8362	2107	63478544
Periorbital haematoma	22.53	17.39	7	8364	787	63479864
Noninfective gingivitis	22.12	17.39	8	8363	1433	63479218
Product dispensing issue	21.86	17.39	5	8366	172	63480479
Tachycardia	21.66	17.39	48	8323	118108	63362543
Acute kidney injury	21.61	17.39	80	8291	263335	63217316
Metabolic acidosis	21.37	17.39	28	8343	45041	63435610
Overdose	21.37	17.39	47	8324	115031	63365620
N-terminal prohormone brain natriuretic peptide	21.26	17.39	4	8367	51	63480600
Diastolic dysfunction	20.59	17.39	12	8359	6459	63474192
Overweight	20.57	17.39	10	8361	3741	63476910
Brain oedema	20.22	17.39	16	8355	14179	63466472
Rhythm idioventricular	19.84	17.39	5	8366	261	63480390
Sinus arrest	19.77	17.39	8	8363	1941	63478710
pH body fluid abnormal	19.48	17.39	4	8367	82	63480569
Myocardial ischaemia	19.41	17.39	15	8356	12844	63467807
Cardioversion	19.36	17.39	7	8364	1253	63479398
Supraventricular tachycardia	18.03	17.39	15	8356	14256	63466395
Arthralgia	17.70	17.39	30	8341	569680	62910971

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged	263.33	18.25	73	5219	4821	34946818
Bradycardia	135.78	18.25	103	5189	75315	34876324
Electrocardiogram PR prolongation	105.64	18.25	25	5267	870	34950769
Atrial fibrillation	91.17	18.25	102	5190	122291	34829348
Drug interaction	73.30	18.25	126	5166	225820	34725819
Palpitations	59.70	18.25	49	5243	39937	34911702
Facial asymmetry	58.87	18.25	13	5279	330	34951309
Ventricular tachycardia	56.01	18.25	40	5252	26539	34925100
Accidental exposure to product by child	40.07	18.25	13	5279	1463	34950176
Neonatal pneumonia	39.79	18.25	8	5284	127	34951512
Atrioventricular block first degree	39.44	18.25	19	5273	6073	34945566
Neonatal hypotension	38.33	18.25	8	5284	154	34951485
Arrhythmia	35.78	18.25	35	5257	35773	34915866
Ventricular arrhythmia	35.05	18.25	17	5275	5511	34946128
Dizziness	34.48	18.25	91	5201	218430	34733209
Haematuria	32.56	18.25	39	5253	50027	34901612
Atrial flutter	31.79	18.25	23	5269	15551	34936088
Brugada syndrome	29.89	18.25	9	5283	792	34950847
Syncope	28.18	18.25	50	5242	91401	34860238
Bundle branch block right	27.45	18.25	16	5276	7500	34944139
Dry mouth	27.40	18.25	28	5264	30137	34921502
Speech disorder	25.45	18.25	25	5267	25661	34925978
Electrocardiogram QT prolonged	25.15	18.25	31	5261	40921	34910718
Nodal arrhythmia	24.92	18.25	8	5284	870	34950769
Heart rate irregular	24.89	18.25	20	5272	15787	34935852
Drug level increased	24.73	18.25	23	5269	22073	34929566
Accidental overdose	24.56	18.25	22	5270	20118	34931521
Completed suicide	24.43	18.25	49	5243	98119	34853520
Respiratory disorder neonatal	23.62	18.25	9	5283	1621	34950018
Toxicity to various agents	23.42	18.25	75	5217	200287	34751352
Hypotension	22.40	18.25	79	5213	221570	34730069
Transient ischaemic attack	22.16	18.25	24	5268	27589	34924050
Generalised tonic-clonic seizure	21.71	18.25	21	5271	21153	34930486
Ventricular asystole	21.40	18.25	5	5287	164	34951475
Sopor	20.49	18.25	16	5276	12120	34939519
Cholestatic liver injury	20.39	18.25	9	5283	2355	34949284
Sinus bradycardia	19.56	18.25	16	5276	12947	34938692
Supraventricular tachycardia	19.51	18.25	15	5277	11102	34940537
Cardiac flutter	19.09	18.25	8	5284	1845	34949794
Loss of consciousness	19.07	18.25	40	5252	82627	34869012

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged	431.01	16.03	129	12464	10704	79721091
Bradycardia	236.46	16.03	185	12408	135372	79596423
Atrial fibrillation	218.77	16.03	208	12385	197678	79534117
Drug interaction	208.77	16.03	290	12303	414893	79316902
Sinus bradycardia	106.79	16.03	60	12533	25187	79706608
Electrocardiogram PR prolongation	99.70	16.03	27	12566	1556	79730239
Arrhythmia	92.57	16.03	77	12516	61195	79670600
Ventricular tachycardia	81.19	16.03	61	12532	41874	79689921
Completed suicide	80.13	16.03	141	12452	245626	79486169
Palpitations	79.61	16.03	99	12494	126511	79605284
Toxicity to various agents	72.26	16.03	186	12407	421354	79310441
Syncope	67.79	16.03	110	12483	179339	79552456
Atrial flutter	66.87	16.03	42	12551	21583	79710212
Atrioventricular block first degree	64.81	16.03	34	12559	12457	79719338
Cardiac arrest	58.98	16.03	101	12492	171995	79559800
Generalised tonic-clonic seizure	57.78	16.03	51	12542	43859	79687936
Nodal arrhythmia	51.27	16.03	17	12576	1961	79729834
Hypotension	51.02	16.03	169	12424	440148	79291647
Dizziness	48.98	16.03	188	12405	526253	79205542
Facial asymmetry	46.96	16.03	13	12580	813	79730982
Enzyme induction	46.42	16.03	9	12584	112	79731683
Brugada syndrome	46.00	16.03	14	12579	1224	79730571
Loss of consciousness	45.43	16.03	89	12504	167854	79563941
Bundle branch block right	42.90	16.03	25	12568	11226	79720569
Intentional overdose	41.40	16.03	66	12527	105894	79625901
Retro-orbital neoplasm	39.73	16.03	7	12586	49	79731746
International normalised ratio increased	39.07	16.03	57	12536	84664	79647131
Heart rate irregular	37.20	16.03	35	12558	32644	79699151
Electrocardiogram abnormal	36.11	16.03	26	12567	16711	79715084
Conduction disorder	35.58	16.03	15	12578	3364	79728431
Neonatal pneumonia	35.45	16.03	6	12587	32	79731763
Asthenia	35.34	16.03	167	12426	511522	79220273
Neonatal hypotension	35.30	16.03	6	12587	33	79731762
Drug level increased	33.26	16.03	36	12557	39615	79692180
Haematuria	32.74	16.03	47	12546	68789	79663006
Bradyarrhythmia	32.64	16.03	15	12578	4131	79727664
Ventricular arrhythmia	32.01	16.03	19	12574	8821	79722974
Respiratory disorder neonatal	31.97	16.03	6	12587	62	79731733
Atrioventricular block complete	31.77	16.03	24	12569	16586	79715209
Electrocardiogram QT prolonged	30.86	16.03	53	12540	90333	79641462
Accidental exposure to product by child	30.85	16.03	13	12580	2913	79728882
Pain	29.45	16.03	41	12552	703761	79028034
Bundle branch block left	27.42	16.03	19	12574	11494	79720301
Presyncope	25.60	16.03	32	12561	41022	79690773
Arthralgia	25.24	16.03	32	12561	571771	79160024
Sinus arrest	25.10	16.03	12	12581	3610	79728185
Cardiogenic shock	25.07	16.03	32	12561	41882	79689913
Muscle mass	24.99	16.03	7	12586	457	79731338
Systolic dysfunction	24.57	16.03	12	12581	3783	79728012
Cardiac assistance device user	24.11	16.03	5	12588	89	79731706
Atrioventricular block	24.04	16.03	19	12574	14022	79717773
Tension	22.88	16.03	12	12581	4392	79727403
Rheumatoid arthritis	22.77	16.03	3	12590	208467	79523328
Flat affect	21.29	16.03	9	12584	2032	79729763
Coagulation test abnormal	21.25	16.03	8	12585	1337	79730458
Myocardial ischaemia	21.11	16.03	23	12570	25496	79706299
Supraventricular tachycardia	20.86	16.03	21	12572	21249	79710546
Cardio-respiratory arrest	20.72	16.03	50	12543	108460	79623335
Small for dates baby	20.36	16.03	6	12587	470	79731325
Product dispensing issue	20.09	16.03	5	12588	206	79731589
Suicide attempt	20.07	16.03	42	12551	82890	79648905
Periorbital haematoma	19.88	16.03	7	12586	967	79730828
Noninfective gingivitis	19.72	16.03	8	12585	1628	79730167
N-terminal prohormone brain natriuretic peptide	19.41	16.03	4	12589	69	79731726
Rash	19.26	16.03	39	12554	578319	79153476
Metabolic acidosis	19.05	16.03	41	12552	82488	79649307
Low birth weight baby	18.76	16.03	6	12587	617	79731178
Rhythm idioventricular	18.75	16.03	6	12587	618	79731177
Mental status changes	18.70	16.03	36	12557	66923	79664872
Haemodynamic instability	18.61	16.03	18	12575	17364	79714431
Bradykinesia	18.51	16.03	13	12580	8030	79723765
Ventricular asystole	18.38	16.03	5	12588	293	79731502
Duplicate therapy error	18.23	16.03	5	12588	302	79731493
Ischaemic stroke	17.80	16.03	24	12569	33107	79698688
Tachycardia	17.70	16.03	65	12528	177703	79554092
Overdose	17.22	16.03	66	12527	184140	79547655
Seizure	17.11	16.03	67	12526	188767	79543028
pH body fluid abnormal	17.08	16.03	4	12589	127	79731668
Transient ischaemic attack	16.81	16.03	30	12563	52665	79679130
Psychomotor retardation	16.62	16.03	11	12582	6173	79725622
Granulocytopenia	16.49	16.03	14	12579	11417	79720378
Labelled drug-drug interaction medication error	16.36	16.03	21	12572	27629	79704166
Atrial thrombosis	16.30	16.03	9	12584	3647	79728148
Cholestatic liver injury	16.29	16.03	10	12583	4931	79726864
Ischaemic hepatitis	16.28	16.03	9	12584	3655	79728140
Off label use	16.23	16.03	81	12512	907134	78824661

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01BC03	CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ic
FDA EPC	N0000175426	Antiarrhythmic
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026941	Sodium Channel Blockers
MeSH PA	D061567	Voltage-Gated Sodium Channel Blockers
CHEBI has role	CHEBI:38070	antiarrhythmic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atrial fibrillation	indication	49436004	DOID:0060224
Paroxysmal supraventricular tachycardia	indication	67198005
Paroxysmal atrial fibrillation	indication	282825002
Paroxysmal atrial flutter	indication	427665004
Life-Threatening Ventricular Tachycardia	indication
Cardioversion of Atrial Fibrillation	off-label use
Bronchospasm	contraindication	4386001
Bundle branch block	contraindication	6374002
Hyperkalemia	contraindication	14140009
Agranulocytosis	contraindication	17182001	DOID:12987
Myocardial infarction	contraindication	22298006	DOID:5844
Torsades de pointes	contraindication	31722008
Sick sinus syndrome	contraindication	36083008	DOID:13884
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Prolonged QT interval	contraindication	111975006
Structural disorder of heart	contraindication	128599005
Atrioventricular block	contraindication	233917008	DOID:0050820
Disease of liver	contraindication	235856003	DOID:409
Severe chronic obstructive pulmonary disease	contraindication	313299006
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN	BLOCKER	IC50	5.48	CHEMBL	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	6.69	DRUG MATRIX	CHEMBL
Sodium channel subunit beta-1	Ion channel	Q07699	SCN1B_HUMAN				WOMBAT-PK
Sodium channel subunit beta-2	Ion channel	O60939	SCN2B_HUMAN				WOMBAT-PK
Sodium channel subunit beta-3	Ion channel	Q9NY72	SCN3B_HUMAN				WOMBAT-PK
Sodium channel subunit beta-4	Ion channel	Q8IWT1	SCN4B_HUMAN				WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.96	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.10	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		ED50	7.06	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.52	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.03	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.73	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.24	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.70	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.06	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.60	WOMBAT-PK
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	6.50	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.83	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5.34	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.60	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.48	DRUG MATRIX
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN		IC50	5.12	CHEMBL
Potassium voltage-gated channel subfamily A member 5	Ion channel	P22460	KCNA5_HUMAN	BLOCKER	IC50	4.40	IUPHAR
Potassium channel subfamily K member 3	Ion channel	O14649	KCNK3_HUMAN		IC50	5.29	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.95	CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	Ion channel	Q9Y3Q4	HCN4_HUMAN		IC50	4.85	WOMBAT-PK
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.60	WOMBAT-PK
Sulfonylurea receptor 2, Kir6.2	Ion channel	O60706 Q14654	ABCC9_HUMAN KCJ11_HUMAN		IC50	5.66	CHEMBL
Nuclear receptor subfamily 2 group E member 1	Nuclear hormone receptor	Q9Y466	NR2E1_HUMAN		EC50	4.33	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	7.44	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.85	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	5.21	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.79	CHEMBL

External reference:

ID	Source
4019911	VUID
N0000147996	NUI
D00640	KEGG_DRUG
34183-22-7	SECONDARY_CAS_RN
4019487	VANDF
4019911	VANDF
C0033429	UMLSCUI
CHEBI:63619	CHEBI
CHEMBL631	ChEMBL_ID
DB01182	DRUGBANK_ID
CHEMBL1201063	ChEMBL_ID
D011405	MESH_DESCRIPTOR_UI
4932	PUBCHEM_CID
2561	IUPHAR_LIGAND_ID
3312	INN_ID
68IQX3T69U	UNII
203135	RXNORM
40681	MMSL
40682	MMSL
5368	MMSL
d00358	MMSL
003525	NDDF
004487	NDDF
108501006	SNOMEDCT_US
372910007	SNOMEDCT_US
96300001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0823	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0823	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0824	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0824	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0826	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	NDA	29 sections
RYTHMOLSR	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0826	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	NDA	29 sections
Propafenone HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0582	TABLET, FILM COATED	150 mg	ORAL	ANDA	29 sections
Propafenone HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0583	TABLET, FILM COATED	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2285	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2286	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2287	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5448	TABLET, FILM COATED	150 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5448	TABLET, FILM COATED	150 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5449	TABLET, FILM COATED	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5449	TABLET, FILM COATED	225 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5450	TABLET, FILM COATED	300 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5450	TABLET, FILM COATED	300 mg	ORAL	ANDA	29 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0740	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0740	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0741	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0741	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0742	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	30 sections
Propafenone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0742	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	30 sections
PROPAFENONE HYDROCHLORIDE	Human Prescription Drug Label	1	16571-736	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	30 sections
PROPAFENONE HYDROCHLORIDE	Human Prescription Drug Label	1	16571-737	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	30 sections
PROPAFENONE HYDROCHLORIDE	Human Prescription Drug Label	1	16571-738	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	30 sections
propafenone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-825	CAPSULE, EXTENDED RELEASE	225 mg	ORAL	ANDA	29 sections
propafenone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-826	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	29 sections
propafenone hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-827	CAPSULE, EXTENDED RELEASE	425 mg	ORAL	ANDA	29 sections
Propafenone	HUMAN PRESCRIPTION DRUG LABEL	1	21695-814	CAPSULE, EXTENDED RELEASE	325 mg	ORAL	ANDA	21 sections